An investigation of the correlation between blood concentration of mizoribine and its efficacy in treatment of rheumatoid arthritis based on indices of drug survival and improvement in DAS28-CRP-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An investigation of the correlation between blood concentration of mizoribine and its efficacy in treatment of rheumatoid arthritis based on indices of drug survival and improvement in DAS28-CRP

Published:2012-11 Issue:6 Volume:22 Page:837-843
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Ohtsubo Hideo¹,Ohkura Sanae¹,Akimoto Masaki¹,Arishima Yoshiya¹,Sunahara Nobuhiko¹,Izumihara Tomomaro²,Eiraku Nobutaka³,Yoshitama Tamami⁴,Matsuda Takemasa¹

Affiliation:

1. Center for Rheumatic Diseases, Japanese Red Cross Society Kagoshima Hospital, 2545 Hirakawa, Kagoshima 891-0133, Japan

2. Izumihara Rheumatoid Arthritis and Internal Medicine Clinic, Kagoshima, Japan

3. Eiraku Internal Medicine Clinic, Kagoshima, Japan

4. Yoshitama Rheumatoid Arthritis and Internal Medicine Clinic, Kagoshima, Japan

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.3109/s10165-012-0611-3

Reference9 articles.

1. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission

2. Efficacy and Safety of Mizoribine by One Single Dose Administration for Patients with Rheumatoid Arthritis

3. Efficacy and safety of single-dose mizoribine for patients with rheumatoid arthritis: results at 6 months after switching from a multiple-dose regimen without a change in total daily dose

4. High-dose mizoribine treatment for adolescents with systemic lupus erythematosus

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP